Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03880422
Other study ID # I 72118
Secondary ID NCI-2019-00341I
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2, 2019
Est. completion date May 2, 2029

Study information

Verified date May 2024
Source Roswell Park Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.


Description:

PRIMARY OBJECTIVES: I. Assess the effect of individualized nutrition and exercise counseling interventions on myokine expression and body composition in prostate cancer (PrCa) patients being treated with androgen deprivation therapy (ADT). SECONDARY OBJECTIVES: I. Determine any changes in muscle strength, respiratory muscle strength and functional capacity resulting from the nutrition and exercise counseling interventions. II. Determine any changes in myokines, circulating inflammatory and frailty-associated cytokines resulting from the nutrition and exercise counseling interventions. III. Determine the effect of the study interventions on dietary intake, physical activity, fatigue, and quality of life. EXPLORATORY OBJECTIVES: I. Correlate changes in secondary objectives with prostate specific antigen (PSA) and testosterone levels. II. Evaluate adherence to nutrition and exercise advice. III. Evaluate assessment tools and recruiting strategies. OUTLINE: Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 2, 2029
Est. primary completion date May 2, 2029
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Biopsy-confirmed prostate adenocarcinoma of any stage/grade - Prescribed or already receiving continuous ADT for < 5 years - Hemoglobin > 11 g/dL - Creatinine < 1.5 x upper limit of normal (ULN), AST or ALT <2 x ULN within 6 months prior to enrollment - Liver function tests < 2 x ULN - Body mass index (BMI) > 25.0 (overweight and obese) - Able to walk unassisted at least 100 meters (200 steps) or ECOG <= 1 - No contraindications to any aspect of participation, including aerobic exercise - Participant must be able to read, write, and understand the English language and be able to provide written consent - Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: - Known clinically significant severe chronic obstructive pulmonary disease (COPD), ischemic heart disease, congestive heart failure, and/or significant cardiac arrhythmias - Limiting orthopedic, musculoskeletal or psychological conditions (clinician discretion) - Overall medical frailty (clinician discretion) - Patients on ADT with concurrent chemotherapy, immunotherapy and/or radiotherapy. Palliative radiation okay. - Any condition contraindicating additional blood collection beyond standard of care - Unwilling or unable to follow protocol requirements - Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Study Design


Related Conditions & MeSH terms

  • Cancer Survivor
  • Frailty
  • Obesity
  • Overweight
  • Prostate Adenocarcinoma
  • Prostatic Neoplasms
  • Stage A Prostate Cancer
  • Stage B Prostate Cancer
  • Stage C Prostate Cancer
  • Stage D Prostate Cancer
  • Stage I Prostate Cancer
  • Stage II Prostate Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer
  • Stage IIC Prostate Cancer
  • Stage III Prostate Cancer
  • Stage IIIA Prostate Cancer
  • Stage IIIB Prostate Cancer
  • Stage IIIC Prostate Cancer
  • Stage IV Prostate Cancer
  • Stage IVA Prostate Cancer
  • Stage IVB Prostate Cancer

Intervention

Dietary Supplement:
Dietary Intervention
Receive diet plan
Other:
Educational Intervention
Attend educational meeting
Behavioral:
Exercise Intervention
Complete exercise program
Other:
Quality-of-Life Assessment
Ancillary studies
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York

Sponsors (1)

Lead Sponsor Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Serum prostate specific antigen (PSA) and androgen levels Will evaluate the association between changes in the primary biomarkers with serum PSA and androgen levels. Up to 6 months
Other Adherence to nutrition and exercise advice Adherence to advice is qualitative in nature and will be summarized using the appropriate descriptive statistics. Up to 6 months
Primary Changes in body composition Will be measured by dual X-ray absorptiometry (DXA) total body and regional lean mass, fat mass and % body fat. Baseline up to 6 months
Secondary Changes in muscle strength Will be assessed by chest press, leg press, grip strength,6-minute walk test, timed-up-and-go, agility, Berg balance scale, short physical performance battery (SPPB). Baseline up to 6 months
Secondary Changes in functional capacity muscle strength Improvement of muscle strenght Baseline up to 6 months
Secondary Change in body composition All subjects will undergo dual-energy X-ray absorptiometry (DEXA) for measurements of body composition Baseline up to 6 months
Secondary myokines concentration Will be assessed by serum biomarker levels. Baseline up to 6 months
Secondary cytokines concentration Will be assessed by serum biomarker levels. Baseline up to 6 months
Secondary Health related quality of life Short Form Will be used to assess quality of life . The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100, Lower scores = more disability, higher scores = less disability Up to 6 months
Secondary Changes in dietary intake Will be assessed by National Cancer Institute Automated Self-Administered 24-hour survey. Baseline up to 6 months
Secondary Changes in physical activity Will be assessed by Godin Leisure Time survey and Fitbit activity report. Will be summarized by time point using the observed sample size, mean, and standard deviation. Will be evaluated using a two-sided permutation paired t-test. Additionally, the mean change in each outcome will be estimated using a 95% confidence interval. As exploratory analyses, the association between the change in each outcome and demographic/clinical factors may be evaluated using general linear models. The change in outcome will be modeled as a function of baseline levels and each demographic/clinical factor in a one-at-a-time manner. Baseline up to 6 months
Secondary Change in fatigue Will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue survey. Baseline up to 6 months
Secondary Change in Respiratory Muscle Strength Mouth pressure device Baseline up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2